Nancy A Dreyer (Nancy Dreyer)

ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 18

Top Venues

JMIR diabetes

Therapeutic innovation & regulatory science

Pharmacoepidemiology and drug safety

JMIR public health and surveillance

IQVIA

University of North Carolina at Chapel Hill (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

IQVIA Oct 11 2011

United States

Chief Scientific Officer :: Real-World & Analytic Solutions

Education History

University of North Carolina at Chapel Hill Jul 20 1974 - Dec 31 1978

United States

PHD :: Epidemilog

Publications

Nancy A Dreyer, Stella C F Blackburn
Power to the people: why person-generated health data are important for pharmacoepidemiology. American journal of epidemiology 193 (9) (2024)
Nancy A Dreyer, Kendall B Knuth, Yiqiong Xie, Matthew W Reynolds, Christina DeFilippo Mack
COVID-19 Vaccination Reactions and Risk of Breakthrough Infections Among People With Diabetes: Cohort Study Derived From Community Reporters. JMIR diabetes 9 (2024)
Nancy A Dreyer, Kendall B Knuth, Yiqiong Xie, Matthew W Reynolds, Christina DeFilippo Mack
COVID-19 Vaccination Reactions and Risk of Breakthrough Infections Among People With Diabetes: Cohort Study Derived From Community Reporters. JMIR diabetes 9 (2024)
Nancy A Dreyer, Kendall B Knuth, Yiqiong Xie, Matthew W Reynolds, Christina DeFilippo Mack
COVID-19 Vaccination Reactions and Risk of Breakthrough Infections Among People With Diabetes: Cohort Study Derived From Community Reporters. JMIR diabetes 9 (2024)
Nancy A Dreyer, Kendall B Knuth, Yiqiong Xie, Matthew W Reynolds, Christina DeFilippo Mack
COVID-19 Vaccination Reactions and Risk of Breakthrough Infections Among People With Diabetes: Cohort Study Derived From Community Reporters. JMIR diabetes 9 (2024)
Nancy A Dreyer, Christina D Mack
Tactical Considerations for Designing Real-World Studies: Fit-for-Purpose Designs That Bridge Research and Practice. Pragmatic and observational research 14 (2023)
Matthew W Reynolds, Yiqiong Xie, Kendall B Knuth, Christina DeFilippo Mack, Emma Brinkley, Stephen Toovey, Nancy A Dreyer
COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness. Infection and drug resistance 15 (2022)
Matthew W Reynolds, Alex Secora, Alice Joules, Lisa Albert, Emma Brinkley, Tom Kwon, Christina DeFilippo Mack, Stephen Toovey, Nancy A Dreyer
Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case-control design. Journal of comparative effectiveness research 11 (16) (2022)
Nancy A Dreyer, Natalia Petruski-Ivleva, Lisa Albert, Damir Mohamed, Emma Brinkley, Matthew Reynolds, Stephen Toovey
Identification of a Vulnerable Group for Post-Acute Sequelae of SARS-CoV-2 (PASC): People with Autoimmune Diseases Recover More Slowly from COVID-19. International journal of general medicine 14 (2021)
Christina Mack, Jennifer B Christian, Emma Brinkley, Edward J Warren, Marni Hall, Nancy A Dreyer
When Context Is Hard to Come By: External Comparators and How to Use Them. Therapeutic innovation & regulatory science 54 (4) (2020)
Nancy A Dreyer, Marni Hall, Jennifer B Christian
Modernizing Regulatory Evidence with Trials and Real-World Studies. Therapeutic innovation & regulatory science 54 (5) (2020)
Jennifer B Christian, Emily S Brouwer, Cynthia J Girman, Dimitri Bennett, Kourtney J Davis, Nancy A Dreyer
Masking in Pragmatic Trials: Who, What, and When to Blind. Therapeutic innovation & regulatory science 54 (2) (2020)
Kristin M Sheffield, Nancy A Dreyer, James F Murray, Douglas E Faries, Megan N Klopchin
Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions. Journal of comparative effectiveness research 9 (15) (2020)
Christina Mack, Jennifer B Christian, Emma Brinkley, Edward J Warren, Marni Hall, Nancy A Dreyer
When Context Is Hard to Come By: External Comparators and How to Use Them. Therapeutic innovation & regulatory science (2019)
Elodie Baumfeld Andre, Robert Reynolds, Patrick Caubel, Laurent Azoulay, Nancy A Dreyer
Trial designs using real-world data: The changing landscape of the regulatory approval process. Pharmacoepidemiology and drug safety 29 (10) (2019)
Cynthia J Girman, Mary E Ritchey, Wei Zhou, Nancy A Dreyer
Considerations in characterizing real-world data relevance and quality for regulatory purposes: A commentary. Pharmacoepidemiology and drug safety 28 (4) (2018)
Hisashi Urushihara, Louise Parmenter, Shimon Tashiro, Kenji Matsui, Nancy A Dreyer
Bridge the gap: The need for harmonized regulatory and ethical standards for postmarketing observational studies. Pharmacoepidemiology and drug safety 26 (11) (2017)
Jonathan Luke Richardson, Sally Stephens, Simon Hugh Lynton Thomas, Anna Jamry-Dziurla, Lolkje de Jong-van den Berg, Priscilla Zetstra-van der Woude, Maja Laursen, Valerie Hliva, Shahrul Mt-Isa, Alison Bourke, Nancy A Dreyer, Stella C F Blackburn
An International Study of the Ability and Cost-Effectiveness of Advertising Methods to Facilitate Study Participant Self-Enrolment Into a Pilot Pharmacovigilance Study During Early Pregnancy. JMIR public health and surveillance 2 (1) (2016)
Nancy A Dreyer, Stella C F Blackburn, Valerie Hliva, Shahrul Mt-Isa, Jonathan Luke Richardson, Anna Jamry-Dziurla, Alison Bourke, Rebecca Johnson
Balancing the interests of patient data protection and medication safety monitoring in a public-private partnership. JMIR medical informatics 3 (2) (2015)
Nancy A Dreyer, Stella C F Blackburn, Shahrul Mt-Isa, Jonathan Luke Richardson, Simon Hugh Lynton Thomas, Maja Laursen, Priscilla Zetstra-van der Woude, Anna Jamry-Dziurla, Valerie Hliva, Alison Bourke, Lolkje de Jong-van den Berg
Direct-to-Patient Research: Piloting a New Approach to Understanding Drug Safety During Pregnancy. JMIR public health and surveillance 1 (2) (2015)

Nancy A Dreyer.css-eqlu8i{font-size:small;padding-left:4px;} (Nancy Dreyer)

Publication Activity (10 Years)

Top Topics

Top Venues

Nancy A Dreyer (Nancy Dreyer)